Form 4: Neurogene Director Cory Freedland Granted 12,050 Stock Options

Neurogene Inc. director and 10% owner Cory S. Freedland was granted 12,050 non-qualified stock options with an exercise price of $20.40, vesting monthly over one year.

Summary

• Cory S. Freedland, a Director and 10% Owner of Neurogene Inc. (NGNE), was granted 12,050 non-qualified stock options.
• The options have an exercise price of $20.40 per share.
• The transaction date for the grant was June 12, 2025.
• These options will vest monthly, with 1/12 of the total shares vesting each month, starting July 12, 2025.
• Full vesting is expected by June 12, 2026, contingent on Mr. Freedland's continued service to the company.
• The options have an expiration date of June 12, 2035.
• A Power of Attorney was executed by Cory Freedland on June 12, 2025, authorizing specific individuals to handle his SEC Forms 3, 4, and 5 filings.

Sentiment

Score: 6

Explanation: The document reports a routine equity grant to a director, which is a positive for aligning interests and retention, but does not contain information that would significantly alter the company's fundamental outlook or financial position. It's a standard compensation event.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The vesting schedule encourages retention of key personnel like Mr. Freedland, ensuring continued service to the company.

Negatives

• No direct negatives are apparent from this routine insider transaction filing.

Risks

• The value of the stock options is subject to the future performance of Neurogene Inc.'s common stock, and there is no guarantee of profitability upon exercise.
• Vesting of the options is contingent on continued service, meaning the options could be forfeited if the reporting person ceases to provide service before full vesting.

Future Outlook

The stock options are subject to a vesting schedule, with 1/12 of the shares vesting monthly from July 12, 2025, until fully vested on June 12, 2026, contingent on continued service. The options expire on June 12, 2035.

Industry Context

Granting stock options to directors and key personnel is a common practice in the biotechnology and pharmaceutical industries, including gene therapy companies like Neurogene Inc., to attract, retain, and incentivize talent, aligning their interests with long-term company performance and shareholder value creation.

Comparison to Industry Standards

• Granting stock options as part of director compensation is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The specific terms, including the exercise price and vesting schedule, are typical for such equity grants, aiming to incentivize long-term commitment and performance.
• No specific comparable companies, projects, or results are mentioned in the document to allow for a detailed, direct comparison.

Corporate Governance

Related Party Transactions

• The grant of non-qualified stock options to Cory S. Freedland, a director and 10% owner of Neurogene Inc., constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The option grant aligns the director's interests with shareholders by incentivizing long-term stock performance. It also represents potential future dilution if options are exercised, though this is a standard component of equity compensation.
• Employees: While not directly impacting general employees, this grant reflects the company's compensation strategy for its leadership, which can indirectly influence overall compensation philosophy.

Next Steps

• Monthly vesting of 1/12 of the granted options will occur starting July 12, 2025, until full vesting on June 12, 2026.
• The reporting person is expected to continue providing service to the Issuer for the options to vest.

Key Dates

Recommendation

Keywords

Neurogene Inc., NGNE, Stock Option, Form 4, Insider Transaction, Director Compensation, Equity Grant, Vesting, SEC Filing, Cory S. Freedland